Table 1.
Clinical characteristics, treatment regimens and outcomes of COVID-19 patients with invasive CRAB infections
| Patient | Age | Sex | Type of infection | ICU | Charlson co-morbidity index | SOFA score | ECMO | Initial three-drug treatment regimen (treatment duration in days) | Clinical outcome | Microbiologic failurea | Recurrent pneumonia | Antibiotic-associated AKIb | 30-day mortality | Inpatient mortality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCU-1 | 20 | M | BSI | Yes | 0 | 17 | Yes | SUL + MEM + PMB (14) | Resolution | Yes | — | No | No | No |
| MICU-1 | 26 | M | VAP | Yes | 0 | 15 | No | SUL + MEM + PMB (21) | Failure | Yes | Yes | No | No | No |
| BCU-4 | 58 | M | VAP | Yes | 2 | 12 | Yes | SUL + MEM + PMB (5) | Indeterminate | Yes | Yes | Yes | Yes | Yes |
| MICU-2 | 68 | F | VAP | Yes | 5 | 11 | No | SUL + MEM + PMB (3) | Indeterminate | N/A | No | No | Yes | Yes |
| MICU-7 | 35 | M | VAP | Yes | 0 | 9 | No | SUL + MEM + PMB (10) | Resolution | No | No | Yes | No | No |
| BCU-5 | 36 | M | VAP | Yes | 0 | 8 | Yes | SUL + MEM + PMB (8) | Failure | Yes | Yes | No | No | No |
| MICU-9 | 33 | F | VAP | Yes | 1 | 10 | No | SUL + MEM + PMB (8) | Resolution | N/A | No | No | No | No |
| BCU-6 | 50 | M | VAP | Yes | 1 | 12 | Yes | SUL + MEM + PMB (8) | Indeterminate | Yes | No | No | No | No |
| MICU-11 | 57 | M | VAP | Yes | 2 | 7 | Yes | SUL + MEM + PMB (14) | Resolution | Yes | Yes | No | No | No |
| MICU-13 | 79 | F | BSI | Yes | 6 | 8 | No | SUL + MEM + PMB (14) | Resolution | No | — | No | No | No |
| BCU-8 | 51 | F | VAP | Yes | 3 | 4 | Yes | SUL + MEM + PMB (10) | Resolution | Yes | Yes | Yes | No | No |
| BCU-9 | 52 | M | VAP | Yes | 1 | 7 | Yes | SUL + MEM + PMB (10) | Failure | Yes | Yes | Yes | No | Yes |
| Other2 | 64 | M | HAP | No | 5 | 5 | No | SUL + MEM + PMB (2) | Indeterminate | N/A | No | No | Yes | Yes |
| MICU-3 | 68 | M | VAP | Yes | 3 | 11 | No | SUL + MIN + PMB (3) | Failure | N/A | No | Yes | Yes | Yes |
| MICU-8 | 77 | F | VAP | Yes | 4 | 11 | No | SUL + MIN + PMB (8) | Resolution | No | No | Yes | No | No |
| MICU-12 | 61 | M | VAP | Yes | 7 | 12 | No | SUL + MIN + PMB (10) | Resolution | Yes | Yes | No | No | Yes |
| Other1 | 47 | F | HAP | No | 3 | 4 | No | MEM + MIN + PMB (14) | Resolution | N/A | No | Yes | No | No |
| MICU-10 | 43 | F | BSI | Yes | 1 | 16 | No | SUL + MEM + MIN (35) | Failure | Yes | −c | No | No | Yes |
BSI, bloodstream infection; ECMO, extracorporeal membrane oxygenation; F, female; HAP, hospital-acquired pneumonia; ICU, intensive care unit; M, male; MEM, meropenem; MIN, minocycline; PMB, polymyxin b; SUL, ampicillin-sulbactam; VAP, ventilator-associated pneumonia.
Yes: repeat cultures with CRAB from the respiratory or bloodstream after completion of the initial antibiotic course; No: repeat cultures without CRAB; N/A: repeat cultures not obtained.
Antibiotic associated acute kidney injury defined as a minimum of two increases in serum creatinine of at least 0.5 mg/dL or 50% or greater increase from baseline after several days of antibiotic therapy.
Patient developed CRAB VAP on day 8 of BSI treatment course.